Skip to main content

Advertisement

SpringerLink
Log in

The effects of cytokine-induced killer cells for the treatment of patients with solid tumors: a clinical retrospective study

  • Original Paper
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

Cytokine-induced killer (CIK) cells exert high impact on adoptive immunotherapeutic approaches for malignant tumors. This study aimed to evaluate the effect of adjuvant immunotherapy with CIK cells on the prognosis of solid tumor.

Methods

Peripheral blood mononuclear cells were collected by a blood cell separator from 40 patients, then expanded by priming them with interferon-gamma followed by monoclonal antibody against CD3 and interleukin-2 the next day. The phenotypic patterns of CIK cells were characterized by flow cytometry on days 0, 7, 10, 14 and 21 of incubation, respectively. Then, 5 ml of venous blood was obtained from 40 patients before and after CIK cells were transfused into patients to assess the influence of CIK cells on the percentages of effector cells.

Results

After 14 days of incubation in vitro, the percentages of CD3+, CD8+, CD3+ and CD56+ increased significantly (P < 0.05). The clinical symptoms of 40 patients were improved apparently. The 6-month, 1-year and 3-year overall survival rates were 70.0, 60.0 and 57.5%, respectively.

Conclusions

Our results indicated that CIKs immunotherapy can be an effective adjuvant instrument of the routine therapy of malignancy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  • Calvo V, Rojo S, Aparicio P, Galocha B, Lopez de Castro JA (1988) Avidity dictates the lytic capacity of human cytolytic T lymphocyte clones with similar fine specificity against murine cells expressing HLA-B27 antigen. J Immunol 141(11):3798–3803

    PubMed  CAS  Google Scholar 

  • Chan EW, Cheng SC, Sin FW, Xie Y (2001) Triptolide induced cytotoxic effects on human promyelocytic leukemia, T cell lymphoma and human hepatocellular carcinoma cell lines. Toxicol Lett 122(1):81–87

    Article  PubMed  CAS  Google Scholar 

  • Chen FX, Liu JQ, Zhang NZ, Gong XJ, Zhang GL, Xu YM, Zhou ZH, Wang T, Huang J (2002) Clinical observation on adoptive immunotherapy with autologous cytokine-induced killer cells for advanced malignant tumor. Ai Zheng 21(7):797–801

    PubMed  Google Scholar 

  • Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA (1982) Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 155(6):1823–1841

    Article  PubMed  CAS  Google Scholar 

  • Hui D, Qiang L, Jian W, Ti Z, Da-Lu K (2009) A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma. Dig Liver Dis 41(1):36–41. doi:10.1016/j.dld.2008.04.007

    Article  PubMed  Google Scholar 

  • Kastelan Z, Lukac J, Derezic D, Pasini J, Kusic Z, Sosic H, Kastelan M (2003) Lymphocyte subsets, lymphocyte reactivity to mitogens, NK cell activity and neutrophil and monocyte phagocytic functions in patients with bladder carcinoma. Anticancer Res 23(6D):5185–5189

    PubMed  Google Scholar 

  • Kim HM, Kang JS, Lim J, Park SK, Lee K, Yoon YD, Lee CW, Lee KH, Han G, Yang KH, Kim YJ, Kim Y, Han SB (2007) Inhibition of human ovarian tumor growth by cytokine-induced killer cells. Arch Pharm Res 30(11):1464–1470

    Article  PubMed  CAS  Google Scholar 

  • Leemhuis T, Wells S, Scheffold C, Edinger M, Negrin RS (2005) A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant 11(3):181–187. doi:10.1016/j.bbmt.2004.11.019

    Article  PubMed  Google Scholar 

  • Marten A, Renoth S, von Lilienfeld-Toal M, Buttgereit P, Schakowski F, Glasmacher A, Sauerbruch T, Schmidt-Wolf IG (2001) Enhanced lytic activity of cytokine-induced killer cells against multiple myeloma cells after co-culture with idiotype-pulsed dendritic cells. Haematologica 86(10):1029–1037

    PubMed  CAS  Google Scholar 

  • Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT et al (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313(23):1485–1492. doi:10.1056/NEJM198512053132327

    Article  PubMed  CAS  Google Scholar 

  • Rosenberg SA, Spiess P, Lafreniere R (1986) A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233(4770):1318–1321

    Article  PubMed  CAS  Google Scholar 

  • Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL (1991) Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 174(1):139–149

    Article  PubMed  CAS  Google Scholar 

  • Schmidt-Wolf IG, Lefterova P, Mehta BA, Fernandez LP, Huhn D, Blume KG, Weissman IL, Negrin RS (1993) Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol 21(13):1673–1679

    PubMed  CAS  Google Scholar 

  • Schmidt-Wolf IG, Lefterova P, Johnston V, Huhn D, Blume KG, Negrin RS (1994) Propagation of large numbers of T cells with natural killer cell markers. Br J Haematol 87(3):453–458

    Article  PubMed  CAS  Google Scholar 

  • Shi M, Zhang B, Tang ZR, Lei ZY, Wang HF, Feng YY, Fan ZP, Xu DP, Wang FS (2004) Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma. World J Gastroenterol 10(8):1146–1151

    PubMed  CAS  Google Scholar 

  • Sun S, Li XM, Li XD, Yang WS (2005) Studies on inducing apoptosis effects and mechanism of CIK cells for MGC-803 gastric cancer cell lines. Cancer Biother Radiopharm 20(2):173–180. doi:10.1089/cbr.2005.20.173

    Article  PubMed  CAS  Google Scholar 

  • Takahashi H, Nakada T, Puisieux I (1993) Inhibition of human colon cancer growth by antibody-directed human LAK cells in SCID mice. Science 259(5100):1460–1463

    Article  PubMed  CAS  Google Scholar 

  • Verneris MR, Kornacker M, Mailander V, Negrin RS (2000) Resistance of ex vivo expanded CD3+ CD56+ T cells to Fas-mediated apoptosis. Cancer Immunol Immunother 49(6):335–345

    Article  PubMed  CAS  Google Scholar 

  • Wang W, Epler J, Salazar LG, Riddell SR (2006) Recognition of breast cancer cells by CD8+ cytotoxic T-cell clones specific for NY-BR-1. Cancer Res 66(13):6826–6833. doi:10.1158/0008-5472.CAN-05-3529

    Article  PubMed  CAS  Google Scholar 

  • Wu C, Jiang J, Shi L, Xu N (2008) Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer. Anticancer Res 28(6B):3997–4002

    PubMed  CAS  Google Scholar 

  • Yun YS, Hargrove ME, Ting CC (1989) In vivo antitumor activity of anti-CD3-induced activated killer cells. Cancer Res 49(17):4770–4774

    PubMed  CAS  Google Scholar 

  • Zhang S, Wang EZ, Bai CX, Xu YH (2003) The proliferation profile in vitro and anti-tumor effects of dendritic cells co-culturing with CIK cells. Shi Yan Sheng Wu Xue Bao 36(5):375–380

    PubMed  Google Scholar 

  • Zoll B, Lefterova P, Csipai M, Finke S, Trojaneck B, Ebert O, Micka B, Roigk K, Fehlinger M, Schmidt-Wolf GD, Huhn D, Schmidt-Wolf IG (1998) Generation of cytokine-induced killer cells using exogenous interleukin-2, -7 or -12. Cancer Immunol Immunother 47(4):221–226

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Rd, Nanjing, 210029, People’s Republic of China

    Jinying Zhang, Lingjun Zhu, Juan Wei, Lingxiang Liu, Yongmei Yin, Yanhong Gu & Yongqian Shu

Authors
  1. Jinying Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lingjun Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Juan Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lingxiang Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yongmei Yin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yanhong Gu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yongqian Shu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yongqian Shu.

Additional information

Jinying Zhang and Lingjun Zhu contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhang, J., Zhu, L., Wei, J. et al. The effects of cytokine-induced killer cells for the treatment of patients with solid tumors: a clinical retrospective study. J Cancer Res Clin Oncol 138, 1057–1062 (2012). https://doi.org/10.1007/s00432-012-1179-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-012-1179-1

Keywords

Search

Navigation